Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. (ONC) director and Scientific Advisory Board chair Wang Xiaodong reported multiple equity transactions on September 8, 2026. He exercised options covering 403,351 Ordinary Shares at an exercise price of $2.84 per share, leaving options on 1,210,079 Ordinary Shares outstanding. On the same date, he acquired 31,027 American Depositary Shares (ADS) (each ADS representing 13 Ordinary Shares) through an exercise or conversion and sold a total of 38,287 ADS in a series of open-market transactions at weighted-average prices in the mid-$300s per ADS, executed under a Rule 10b5-1 trading plan adopted on June 9, 2026. Following these transactions, he directly held 4,588,113 Ordinary Shares and also had indirect interests through family-related entities and a family trust, for which he disclaims beneficial ownership.
BeOne Medicines Ltd. (ONC) received a notice that Xiaodong Wang, identified as a director and chair of its Scientific Advisory Board, plans to sell up to 131,370 ADS under Rule 144 through a broker on or after September 8, 2026.
The planned sale consists of 124,110 ADS to be received upon exercise of stock options over the next three months and 7,260 ADS acquired upon vesting of restricted stock units between June 22, 2022 and June 15, 2026. The aggregate market value of the ADS to be sold is stated as $47,064,616.20, with 57,914,782 ADS outstanding.
BeOne Medicines Ltd. (ONC) reported that Principal Accounting Officer Titus B. Ball sold 132 American Depositary Shares on September 1, 2026 at $355.86 per ADS. The sale was effected pursuant to a mandatory tax withholding provision tied to the vesting of a restricted share unit award. Each ADS represents 13 Ordinary Shares, and following this transaction he directly holds 97,929 Ordinary Shares. No Rule 10b5-1 trading plan is reported.
BeOne Medicines Ltd. (ONC) discloses that Titus Benjamin Ball plans to sell 132 American Depositary Shares (ADS) of the company under Rule 144, following restricted stock vesting under a registered plan. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ. Over the prior three months, Titus Benjamin Ball reported sales of 169 ADS on June 11, 2026 for $43,466.56 and 136 ADS on June 8, 2026 for $36,900.64.
BeOne Medicines Ltd. (ONC) officer Wu Xiaobin, President and COO, reported selling 280 American Depositary Shares (ADS) of BeOne Medicines on 2026-08-25 at $380.00 per ADS in an open-market or private transaction. Each ADS represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-11-07. After these transactions, Wu reported direct ownership of 1,270,084 Ordinary Shares and indirect ownership of 4,000 ADS held by his wife.
BeOne Medicines Ltd. (ONC) reported that it filed its 2026 Interim Report for the six months ended June 30, 2026 with the STAR Market of the Shanghai Stock Exchange, prepared under PRC GAAP, and furnished related U.S. GAAP information to U.S. investors. The company summarized key accounting differences between PRC GAAP and U.S. GAAP for share-based compensation, interim income tax calculation, lease presentation and the transfer of future royalty rights from a collaborative arrangement. It also disclosed a detailed U.S. GAAP breakdown of research and development expenses by key products and projects for the first half of 2026, showing total R&D expenses of US$1,153,504,000 versus US$1,006,783,000 a year earlier, including both external project spending and internal R&D costs.
BeOne Medicines Ltd. (ONC) received a notice on Form 144 indicating that officer Xiaobin Wu intends to sell up to 15,000 ADS of BeOne Medicines. The ADS were acquired upon the vesting of restricted stock units during the period from 06/05/2022 through 06/05/2023.
The proposed ADS sale is listed for execution through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a noted date of 08/25/2026. The notice also reports that, during the past three months, Xiaobin Wu sold BeOne common shares in three transactions: 626 shares for $163,512.26 on 06/11/2026, 1,357 shares for $361,996.85 on 06/16/2026, and 1,292 shares for $356,926.89 on 06/23/2026.
BeOne Medicines Ltd. (ONC) has a notice of proposed sale under Rule 144 filed for securities beneficially owned by former director Corazon D. Sanders. The notice covers the planned sale of 2,075 ADS of BeOne Medicines Ltd., with an aggregate market value of $788,500.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after 08/25/2026 on the NASDAQ market. The ADS were acquired by exercise of options under a registered plan for cash. In the preceding three months, Sanders sold 945 shares of common stock of BeOne Medicines Ltd. on 06/15/2026 for aggregate proceeds of $250,893.81.
BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026. He exercised three option grants covering a total of 34,658 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share. In related non-derivative transactions, he acquired blocks of 812, 1,058, and 796 American Depositary Shares (each ADS representing 13 Ordinary Shares), and sold 2,666 ADS at $360.00 per ADS pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. Following these transactions, he directly held 325,312 Ordinary Shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open-market sales of a total of 240,810 American Depositary Shares (ADS) of the company over August 10–12, 2026, in 24 separate transactions at per-share prices generally between $350 and $367. Each ADS represents 13 Ordinary Shares. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Oyler on March 10, 2026. A direct holding line shows 1,330,988 Ordinary Shares held, and additional Ordinary Shares are held indirectly through various trusts and an IRA, some of which Oyler disclaims beneficial ownership of.